期刊文献+

糖链抗原50和242对结直肠癌诊断的价值 被引量:12

Clinical value of carbohydrate antigen 50 and carbohydrate antigen 242 in the diagnosis of colorectal carcinoma
下载PDF
导出
摘要 目的探讨糖链抗原50(CA50)和242(CA242)在结直肠癌诊断中的应用价值。方法应用放免法测定71例结直肠癌患者和48例结直肠良性疾病患者血清中CA50、CA242的水平并进行统计学处理。结果CA50在结直肠良性疾病和结直肠癌中的阳性率分别6.3%和69.0%,CA242的分别为8.3%和73.2%,二者在良恶性病变中的水平均有显著性差异(P<0.001);CA50在结直肠癌未发生转移组和已发生转移组的阳性率分别为52.8%和82.8%,CA242的分别为44.4%和88.6%,二者在未发生和已发生转移组中的水平亦均有显著性差异(P<0.01)。结论CA50和CA242的血清水平在结直肠癌中比结直肠良性疾病中为高,在结直肠癌的晚期比早期为高,对结直肠癌的临床诊断具有一定价值,可和其他血清肿瘤标记物联合检测,互相弥补以提高检出率;也可通过动态观察其血清水平,推测患者病情的进展。 Objective Carbohydrate antigen 50 (CA50) and 242 (CA242), recently recognized as serum tumor markers, are studied for their value in the diagnosis of the colorectal carcinoma. Methods This study included 48 patients with benign bowel disease and 71 patients with colorectal carcinoma, whose serum CA50 and CA242 levels were measured by immunoradiometric assay. Results The total positivity of CA50 and CA242 in colorectal carcinoma cases were 69.0% and 73.2% respectively, and were only 6.3% and 8.3% in benign cases. In non-metastatic colorectal carcinoma cases, the positivity rates for CA50 and CA242 were 52.8% and 44.4% respectively, which were 82.8% and 88.6% in cases with metastasis. Marked elevation in CA242 level was noted in the patients with colon carcinoma (77.5%). But at early stage of the malignancy, both tumor markers had low sensitivity. Conclusions CA50 and CA242 are valuable tumor markes in the diagnosis of colorectal carcinoma.
作者 黄聪武 白岚
出处 《第一军医大学学报》 CSCD 北大核心 2002年第12期1116-1118,共3页 Journal of First Military Medical University
基金 广东省自然科学基金(940312)
关键词 诊断 糖链抗原50 糖链抗原242 血清肿瘤标记物 结直肠癌 carbohydrate antigen 50 carbohydrate antigen 242 serum tumor marker colorectal carcinoma
  • 相关文献

参考文献9

  • 1Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibod ies against gastrointestinal tumor-associated antigens isolated as monosialogangliosides [J]. Int Arch Allergy Appl Immunol, 1983, 71(2): 178-81.
  • 2张彬,李庆宏,陈智周,范振符,赵世民,朱争艳,许智雄,倪莉,张月梅.肿瘤标记物CA-50,CA-242和唾液精脒在头颈部肿瘤病人中的测定[J].耳鼻咽喉(头颈外科),1994,1(2):94-98. 被引量:2
  • 3Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA199 for the diagnosis of pancreatic cancer[J]. Br J Cancer, 1994, 70(3): 481-6.
  • 4Palsson B, Masson P, Andren-Sandberg A. The influence ofcholesta sis on CA50 and CA242 in pancreatic cancer and benign biliopancreatic diseases [ J ]. Scand J Gastroenterol, 1993, 28( 11): 981-7.
  • 5Ichihara T, Nomoto S. Clinical usefulness of the immunostaining of the tumor markers in pancreatic cancer [ J ]. Hepatogastroenterology, 2001, 48(40): 939-43.
  • 6Chu JS, Chang KJ. Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast[J]. Cancer Lett, 1999, 142 (1): 121-7.
  • 7Huglund C, Lundin J, Roberts PJ, et cd. CA242, a new tumor marker for pancreatic cancer a comparison with CA199, CA50 and CEA[J]. Br J Cancer, 1994, 70(4): 487-92.
  • 8Watanabe M, Chigusa M, Takahashi H, et al. High level of CA19-9,CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo[J]. In Vitro Cell Dev Biol Anim, 2000, 36(2): 104-9.
  • 9Kuusels, Haglund C, Roberts PJ. Comparison of a new tumour mark er CA242 with CA19-9, CA50 and carcinoembryonic antigen (CEA) in digestive tract diseases [ J ]. Br J Cancer, 1991, 63(4): 636-40.

共引文献1

同被引文献51

引证文献12

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部